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ABSTRACT
Beta protein 1 (BP1), a human homeotic transcrip-
tion factor, is expressed during hematopoeisis in
the erythroid lineage. To determine the in vivo role
of BP1 in erythropoiesis, we have undertaken two
complementary approaches using enforced BP1
expression in both transgenic mice and embryonic
stem (ES) cells. Despite repeated attempts, only
one adult transgenic BP1 founder mouse among
121 mice was obtained. This mouse presumably
survived due to transgene mosaicism because the
transgene could not be transmitted. This mouse
expressed BP1 and displayed splenomegaly,
extramedullary erythropoiesis and severe amyloido-
sis A in the kidney, a phenotype compatible with
thalassemia. Consistently, the presence of BP1
transgene in fetuses was associated with paleness
and lethality. In ES cells, BP1 expression in primary
differentiation appeared to antagonize adult b-globin
globin expression. In secondary differentiation, BP1
expression reduced significantly b-globin gene
expression in both primitive and definitive erythroid
cells, whereas it impaired only the definitive ery-
throid cell differentiation. These studies showed
that BP1 can negatively modulate adult b-globin
gene expression and definitive erythroid cell differ-
entiation, and suggest that BP1 could play a role in
thalassemia.
INTRODUCTION
The transcription factor beta protein 1 (BP1) is a member of
the homeobox gene family and the distal-less subfamily. The
expression of BP1 is highly tissue-speciﬁc and developmen-
tally restricted. Among 50 human tissues, BP1 was highly
expressed in placenta, kidney and at lower levels in fetal liver
(1). Such restricted pattern of expression is compatible with a
speciﬁc gene function in development and/or differentiation.
In transient transfection studies, BP1 protein appears to act
as a repressor of the human adult b-globin gene, through
two silencers upstream of the b-globin gene (1–3). In addi-
tion, BP1 protein was shown to bind to negative control
regions upstream of the adult b-globin gene and the murine
b-major globin gene (4). The clinical relevance of BP1 is sup-
ported by the inverse correlation between the binding afﬁnity
of BP1 protein to polymorphic DNA sequences associated
with sickle cell disease (5). We found that DNA with stronger
BP1 binding in the Indian-Arabo haplotype, or weaker BP1
binding, as in the Bantu haplotype, have respectively,
reduced or increased clinical evidence for red blood cell sick-
ling. Taken together, these studies support the hypothesis that
BP1 is a physiologic repressor of b-globin gene expression.
A role for BP1 in bone marrow hematopoiesis is also
emerging. BP1 is expressed in puriﬁed CD34
  hematopoietic
bone marrow cells, a primitive subpopulation of human
hematopoietic cells, and its expression decreases to unde-
tectable levels during terminal erythropoiesis (1,6). Enforced
expression of BP1 in embryonic/fetal erythroid K562 cells
leads to decreased erythroid differentiation potential, while
ectopic expression of BP1 increases clonogenicity, suggest-
ing a role for BP1 in leukemogenesis. In fact, expression of
BP1 was detected in 63% of primary leukemia blasts from
AML patients and in 32% of leukemic blasts from T-ALL
patients (6).
The aim of this study was to determine the role of BP1 in
erythroid differentiation of transgenic mice and in totipotent
embryonic stem (ES) cells. In ES cells constitutively express-
ing BP1, we demonstrate marked repression in the generation
of deﬁnitive erythroid (E
d) cells with no effect on growth
of the ES-derived embryoid bodies (EB) or in primitive ery-
throid (E
p) cells. Moreover, expression of BP1 in deﬁnitive
erythroid cells in transgenic mice appears incompatible
with survival.
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Constructs
The LCRBP1 construct was produced in p-Bluescript vector
by joining the human b-globin promoter to the 1.1 kb BP1
cDNA (7). Subsequently, the human b-globin 8 kb midi
LCR (8) was linked upstream and the human 2.8 kb b-globin
30 sequences consisting of 18 bp of exon 2, all of exon 3 and
30 ﬂanking sequences were adjoined downstream. The
LCRDBP1 construct was identical to LCRBP1 but without
the BP1 cDNA. A 12 kb Sal I–Not I fragment was puriﬁed
from LCRBP1 to generate transgenic mice in (C57Bl/6J X
CBA/J)F2 mouse strains as described previously (8).
Cell culture and differentiation
CCE-ES cells (gift from Dr G. Keller, NY) were maintained
as described previously (9). ES cells were co-electroporated
(10) using equivalent molar ratios of the LCRBP1 or
LCRDBP1 and the pSV3neo vector and selected with G418
(400 mg/ml). DNA from several independent subclones was
analyzed by Southern blotting with two restriction digests,
SalI/EcoRI and SalI/BamHI, and a BP1–b-globin probe to
verify contiguous integrity. Conditions for erythroid differen-
tiation consist of SCF (100 ng/ml), IL-3 (5 ng/ml) and Epo
(2 U/ml) (11).
RNA extraction and expression analysis
Total RNA was isolated from ES cells using Trizol reagent
(Invitrogen). cDNA synthesis was performed for E
p and E
d
samples by two successive series of oligo(dT)-primers and
PCR ampliﬁcation; for EB samples, 1 mg of RNA was used
as described previously (12).
Semi-quantitative expression analysis for the BP1 trans-
gene and b-globin genes were carried out with the following
primers: for BP1, forward 50-TGGAGCCTGGTATCAGC-
ATC-30 and reverse 50-TGGACAGCAAGAAAGCGAGC-30
(in exon 3 b-globin gene) producing an amplicon of 417 bp;
for b-globin, forward 50-GGACCCAGCGGTACTTTGA-
TAG-30 (exon 2) and reverse 50-GTGGCCCAGCACAAT-
CACGAT-30 (in exon 3) generating a 239 bp product. S16
ribosomal primers were described previously (13). Conditions
for BP1 ampliﬁcation were 94 C, 30 s, 57 C, 30 s, 72 C, 30 s
for 30 cycles; conditions for b-globin and S16 were 94 C,
30 s, 60 C, 30 s, 72 C, 30 s for 14 and 20 cycles and a
ﬁnal elongation of 10 min at 72 C. Radioactive PCR products
were analyzed on 8% polyacrylamide/TBE gel and quantiﬁed
by phosphoimager. For real-time quantitative analysis, the
same primers were used, except the BP1 primers were replaced
with forward 50-CCCCAATTTGTCCTACTCCA-30 and
reverse 50-GGTTGCTGGCAGGACAGGTA-30, and produced
an amplicon of 100 bp. Four series of ES primary and sec-
ondary differentiation experiments were performed with dupli-
cate of each clone in each experiment. All reactions were
performed in triplicate in a master mix (Qiagen, Mississauga,
Canada), containing 0.3 mM of each primer. Ampliﬁcation
conditions were 95 C, 15 min followed by 44 cycles of
94 C, 30 s, 60 C, 35 s, 72 C, 30 s, in a MX3500pro multiplex
quantitative PCR analyzer.
Histological analysis
Age-matched controls and transgenic tissues were formalin-
ﬁxed and embedded in parafﬁn. Tissue sections (5 mm)
were stained with hematoxylin/eosin and Congo red for
light microsopy. Immunoﬂuorescence for IgG, IgM, IgA,
Kappa and Lambda light chains was performed following
pronase digestion of parafﬁn sections. Staining for serum
amyloid A (SAA) protein was performed by immunoperoxi-
dase using avidin–biotin labeling. Tissues for ultrastructural
analysis were ﬁxed in 2.5% glutaraldehyde-buffered with
0.01 M cacodylate (pH 7.4) and postﬁxed in 2% osmium
tetroxide and embedded in Epon. Ultrathin sections were
stained with uranyl acetate and lead citrate (14).
RESULTS AND DISCUSSION
BP1 expression in vivo appears to be embryonic lethal
Characterization of the in vivo role of BP1 in erythroid cells
was undertaken by introducing a LCRBP1 construct into
mice. LCRBP1 was produced by linking the human b-globin
regulatory sequences without the two BP1 silencer regions to
the human BP1 cDNA (Figure 1a). Only one adult founder
transgenic mouse with an intact transgene was generated
from 121 mice (P28 in Table 1). This female founder
mouse appeared to have one copy of the transgene and was
extensively mated with wild-type (C57Bl/6J X CBA/J)F1
mice. From 11 litters, all 76 mice were negative for the
Figure 1. LCRBP1 transgene structure and expression in transgenic mouse.
(a) The LCRBP1 construct was produced in a bluescript vector by joining
the human b-globin promoter (pr) lacking the two silencer sequences
( 264/SnaB1 to +48/NcoI) to the 1.1 kb BP1 cDNA (SmaI–XbaI). The
human b-globin 8 kb midi LCR was linked to this DNA upstream, and
downstream 2.8 kb of the b-globin gene including 30 sequences of exon 2, all
of exon 3, and 30 flanking sequences [BamHI (nt 62613) to XbaI (nt 65421),
GenBank accession no. U01317), containing the two globin 30 enhancers (18).
The probe BP1-b-globin (SnaBI–XbaI, 3.2 kb) used for transgenic mouse
screening by Southern blot analysis is indicated above the LCRBP1 construct.
(b) Expression analysis in peripheral blood using RT–PCR. Three RNA blood
samples from control H2O (C), transgenic mouse (tg BP1) and control
identical mouse strain (WT) were monitored for BP1 and S16 expression.
Human BP1 expression was readily detectable in the blood of the transgenic
founder mouse and undetectable in the blood of the control identical mouse
strain. Expression of the ribosomal protein S16 served as internal control.
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10–12 pups on average for these strains. The lack of transmis-
sion can be explained by high mosaicism and/or embryonic
lethality resulting from BP1 transgene expression. The very
low frequency of adult transgenic mice obtained compared
to the frequency of  10–15% for other transgenes (data not
shown), also indicated that the expression of BP1 in differen-
tiating and mature erythroid cells could be lethal during
gestation. To test this hypothesis, microinjection of additional
oocytes of the LCRBP1 construct was carried out and fetuses
were analyzed for the presence of the transgene at various
stages of gestation. As shown in Table 1, one of two embryos
at E15.5 and four of 27 embryos at E16.5 were LCRBP1
Table 1. Genotype analysis of fetuses/pups from LCRBP1 microinjected
oocytes
Stage (age) Total n (fetuses or pups) BP1 Genotype
  +
E15.5 2 1 1
E16.5 27 23 4
a
E17.5 41 40 1
E18.5 39 38 1
b
P28 121 120 1
c
aAmong 4 fetuses: 1 resorbed and 1 pale.
bFetus completely resorbed.
cMouse does not transmit the transgene.
Figure 2. Histopathological analysis of the LCRBP1 transgenic founder mouse. (a) Normal histology of the kidney displaying small regular glomeruli and
surrounding tubulo-interstitial compartment (H&E, ·100). Inset shows glomerulus of normal size and cellularity with patent capillaries and basement membranes
of normal thickness (H&E, ·400). (b) Renal histology of the transgenic LCRBP1 mouse showed diffuse and uniform enlargement of the glomeruli due to
expansion of the glomerular tuft by amorphous pale eosinophilic material. The outlying tubules, interstitium and blood vessels are uninvolved (H&E, ·100). Inset
shows a representative glomerulus of the transgenic LCRBP1 mouse with expansion of the mesangium and narrowing of the glomerular capillary lumina by
voluminous deposits of amorphous material typical of amyloid. The glomerular cellularity appeared reduced (H&E, ·400). (c) Kidney of the transgenic LCRBP1
mouse viewed under polarized light displayed apple green birefringence diagnostic of amyloid deposits in a diffuse and global glomerular distribution (Congo
red, polarized light, ·100). (d) Kidney of the transgenic LCRBP1 mouse showed strong diffuse and global glomerular positivity for serum amyloid A protein
(SAA immunostain, ·250). (e) Ultrastructural analysis of a normal renal glomerular capillary showed the normal glomerular architecture, without fibrillar
deposits (EM, ·6000). (f) Ultrastructure of a renal glomerulus from the transgenic LCRBP1 mouse showed abundant randomly oriented 8–10 nm fibrils
expanding the mesangial regions and narrowing the adjacent glomerular capillary lumen (EM, ·6000). Inset shows fibrils at higher magnitude (EM, ·20000).
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resorbed and one was pale (anemic). The frequency of trans-
genic fetuses decreased thereafter. Since the maximal expres-
sion of the endogeneous murine adult globin gene occurs at
E16.5 for deﬁnitive erythroid cells, it would be expected
that repression by BP1 would be most detrimental from this
stage onwards.
The only adult female transgenic founder expressed BP1 in
peripheral blood, shown by RT–PCR and Rnase protection
(Figure 1b and data not shown). Pathological analysis
upon the unexpected death of this transgenic founder mouse
showed splenic enlargement by  2-fold compared to the age-
matched control mouse strain. The bone marrow cellularity
was increased by 1.8-fold in the femur of the founder
mouse (8.4 · 10
7cells) relative to controls (4.6 · 10
7 ± 0.9
cells; n ¼ 4) which is consistent with the  1.4-fold increase
in cellularity observed in hemizygous b-globin knock-out
mice, a model of b-thalassemia (15). Both these features
are indicative of stimulated hematopoiesis and consistent
with the observation of numerous foci of extramedullary
hematopoiesis in organs such as spleen and kidney. While
renal tissues had normal tubules, interstitium and blood ves-
sels, the glomeruli showed expansion of the mesangium
compared to controls (Figure 2a and b), with narrowing of
the capillaries due to large Congo red positive amyloid
deposits (Figure 2c and d). By speciﬁc staining for identiﬁca-
tion of amyloid precursor proteins, these amyloid deposits
were negative for immunoglobulins, kappa and lambda
light chains but positive for SAA (Figure 2c and d). Electron
microscopy revealed glomerular deposits of randomly ori-
ented 8–10 nm ﬁbrils typical of amyloid (Figure 2e and f).
Presence of increased SAA is observed in conditions of
chronic inﬂammation as in thalassemia (16). The composite
of these pathologic ﬁndings, increase in erythropoiesis/
hematopoiesis and amyloid deposits, are consistent with a
thalassemic condition in the BP1 transgenic mouse.
BP1 expression impairs definitive erythropoiesis
To gain further insight into the in vivo role of BP1 in primi-
tive and deﬁnitive hematopoiesis, the LCRBP1 and empty
vector control LCRDBP1 constructs were targeted to totipo-
tent ES cells by co-electroporation with the pSV3neo vector.
Several independent clones were obtained for both constructs
and were analyzed by Southern blot for integrity of the trans-
genes (Figure 3). Among the clones with an intact transgene,
three clones for LCRBP1 (1, 2 and 5 transgene copies) and
three clones for LCRDBP1 (1 and 2 copies) were selected
for subsequent analysis.
Parental and electroporated ES cells were differentiated
in vitro to form EBs (which contain a variety of cell types)
and assessed for BP1 expression. The potential of these elec-
troporated ES cells to generate EBs was not signiﬁcantly
affected, as the primary plating efﬁciency was 17.5 ± 3.9%
for parental ES cells, 17.1 ± 4.3% for LCRDBP1 cells and
14.1 ± 3.5% for LCRBP1 cells (mean ± SD). In addition,
LCRBP1 electroporated ES cells yielded similar-sized EBs
as the parental and empty vector ES cells (data not shown),
suggesting that the number of cells per EB was not altered.
During this primary differentiation process, the percentage
of hemoglobinized EBs was comparable between the parental
and electroporated cells at day 9 (Table 2). To quantify
expression levels, we ﬁrst established the RT–PCR conditions
to be within the linear range (Figure 4a). The expression time
course of the endogenous adult b-globin gene was similar
between wild-type and empty vector control (Figure 4b
and data not shown). Noticeably, wild-type ES cells or
EBs with empty LCRDBP1 control did not express BP1
(Figure 4). In two independent experiments, the expression
of BP1 in the LCRBP1 clones was highest at days 6 and
9 and decreased from day 12 onwards whereas the b-globin
Figure 3. Integrity of the BP1 transgene in ES cells. Southern blot analysis of
electroporated ES cells with LCRDBP1 and LCRBP1 constructs. Restriction
enzyme digestion was carried out for LCRDBP1 and LCRBP1 clones using
SalI/BamHI. Probe used is depicted in Figure 1a and spanned the adult
b-globin and BP1 sequences. Expected fragments are 6.1 and 2.8 kb for the
LCRDBP1clones, and 7.2 and 2.8 kb for the LCRBP1 clones. The intensity of
the 6.1 kb band of LCRDBP1 clones is weaker than the 2.8 kb or the 7.2 kb of
the LCRBP1 clones since only  0.3 kb of the probe is homologous to globin.
Extra bands correspond to junction of the constructs with genomic sequences.
M, molecular weight marker l digested with HindIII and C, copy of LCRBP1
unit length.
Table 2. Quantification of erythroid progenitors
EBs d9
% Hb EBs/total EBs
E
p d3
No. E
p/10
5 cells
E
d d7
%E
d/total colonies
WT 53.97 ± 1.45 0.17 ± 0.01 27.00 ± 0.50
LCRDBP1 53.49 ± 3.39 0.18 ± 0.01 25.00 ± 0.35
LCRBP1-1 55.48 ± 8.77 0.17 ± 0.02 17.16 ± 1.75*
,***
LCRBP1-2 54.00 ± 2.82 0.19 ± 0.00 17.50 ± 0.00**
,***
LCRBP1-3 51.35 ± 3.32 0.15 ± 0.02 17.66 ± 0.76**
,***
Analysis was carried out on optimal culture days for EBs (day 9), primitive
erythroid progenitors E
p(day 3), definitive erythroid progenitors E
d (day 7)
from parental or electroporated ES cells as described (9). The proportion of
erythroid CFC was determined in the presence of BP1 expression for EBs
(% hemoglobinized Hb/ EBs), E
p (No. E
p per 10
5 cells) and E
d (% E
d/total
colonies). The data from wild type WT, LCRDBP1 (mean of two clones), or
LCRBP1 from three clones (1–3) are shown as mean ± standard deviation.
P-value: student’s t-test.
Values arecomparedto WT-CCE:*P <0.01,**P <0.001,and to LCRDBP1:
***P < 0.01.
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Semi-quantitative analysis of the LCRBP1 clones indicated
a  1.5- to 2-fold reduction in b-globin expression normalized
to S16 on days 12 and 15 relative to empty vector control.
Consistently, quantiﬁcation by real-time PCR of EBs at day
9 showed a decrease in b-globin expression levels by at
least 4-fold, a time when BP1 is strongest (Table 3 and
Figure 4). Hence the LCRBP1 clones indicated that BP1
might antagonize expression of the murine b-globin gene.
Conversely, repression of BP1 in the erythroleukemic K562
cell line was shown to enhance endogeneous human b-globin
gene expression (3).
To investigate more precisely the role of BP1, we carried
out secondary differentiation under conditions favorable for
erythroid/hematopoietic colony forming cells (CFCs). In four
series of experiments, the number of primitive erythroid E
p
progenitors detected at day 3 was unchanged upon differen-
tiation of parental, LCRBP1 and control LCRDBP1 ES
cells (Table 2). Quantitative expression analysis from pools
of LCRBP1 E
p normalized to S16 showed a signiﬁcant
increase in BP1 expression levels ( 20- to 25-fold) compared
to pools of LCRBP1 EBs (Table 3). As shown in Table 2, this
increase in BP1 expression appeared to exert no signiﬁcant
negative effect on production of primitive erythroid cells.
However, the number of deﬁnitive erythroid-CFC (E
d-CFC)
at day 7, as identiﬁed by hemoglobinized colonies, was sig-
niﬁcantly decreased in LCRBP1 relative to empty vector
and parental ES cells. Pools of individual hemoglobinized
deﬁnitive erythroid E
d LCRBP1 progenitors showed high
BP1 expression levels similar to those observed for primitive
Figure 4. Expression analysis of BP1 and b-globin genes in EBs at various stages of primary differentiation. (a) Demonstration of linearity of RT–PCR
amplification. Varying quantities of total cDNA aliquots were amplified with primers specific for BP1, b-globin and S16 as internal control to ensure that
conditions were within linear range of amplification. The reactions were evaluated semiquantitatively on polyacrylamide gels scanned by phosphoimager and
values plotted on linear graphs. (b) Parental ES cells (WT), ES cells containing the empty vector (LCRDBP1) or ES cells containing BP1 (LCRBP1) were
differentiated into embryoid bodies (EBs). Expression analysis of BP1 and of the endogeneous b-globin gene was carried out by RT–PCR on the indicated days
of differentiation, using S16 expression as an internal control. Days indicated were selected for analysis of the kinetics of erythroid differentiation since primitive
erythroid expression is maximum on day 7 and definitive erythroid lineage expression is high from day 5 to day 12 (11). Semi-quantitative evaluation was carried
out for each sample run on the same gel and normalized to the ribosomal RNA control.
Table 3. Quantitative expression of BP1 and adult b-globin genes in erythroid progenitors
EBs d9 E
p d3 E
d d7
BP1/S16 b-globin(10
 3)/S16 BP1/S16 b-globin/S16 BP1/S16 b-globin/S16
WT N.D. 28 ± 2.6 0.03 ± 0.0 10.0 ± 2.2 N.D. 300.5 ± 7.3
LCRDBP1 N.D. 14 ± 8.5 0.05 ± 0.0 10.3 ± 1.5 N.D. 250.4 ± 4.2
LCRBP1-1 2.7 ± 0.6 2 ± 0.6* 73.8 ± 1.7 3.9 ± 0.3** 60.0 ± 2.8 150.3 ± 14.7**
LCRBP1-2 25.4 ± 4.5 3 ± 0.4* 672.4 ± 19.4 5.1 ± 1.9* 702.3 ± 99.5 225.9 ± 19.2*
LCRBP1-3 5.2 ± 1.8 1 ± 0.1* 126.3 ± 2.0 7.5 ± 2.1* 117.7 ± 22.0 180.8 ± 24.5*
Thedatafromwildtype(WT),LCRDBP1(meanofthreeclones),orLCRBP1fromthreeclones(1to3)are shown.Valuesofreal-timePCRrepresentrelativeunits
normalized to control S16 expression ± standard deviation. N.D.: Not detected.
Statistical significance: *P < 0.05, **P < 0.005, compared to WT.
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p LCRBP1 progenitors by real-time PCR
(Table 3). These results indicated that the elevated BP1
expression led to a speciﬁc decrease of deﬁnitive erythro-
poiesis compared to primitive erythropoiesis. Importantly,
BP1 expression caused a signiﬁcant decrease in adult b-
globin gene expression for both E
p and E
d cells relative to
wild-type and empty vector control, reaching 2- to 2.5-fold
(Table 3). In contrast to deﬁnitive erythropoiesis, the adult
b-globin chain is not the most prevalent b-like globin chain
in primitive erythropoiesis and consistently, decreased
expression had no apparent impact on primitive differentia-
tion. Of note, pools of hemoglobinized erythroid E
d
LCRBP1 progenitors were picked for expression analysis
since non-hemoglobinized colonies include other cell types.
However, pooling hemoglobinized E
d would be expected to
select for higher b-globin levels, possibly skewing the data
toward less repression. Thus, the actual decrease in b-globin
may be much greater than the one observed. Nevertheless,
such a decrease in expression would be likely to have an
important impact in the mouse, since the hemizygous b-
globin knock-out mice with only a 25% reduction in b-globin
gene expression resulted in a severe b-thalassemic phenotype
with half the levels of hemoglobin and hematocrit levels
(15,17). Further, expression of BP1 did not signiﬁcantly
alter the number of mac-CFC (macrophages), mix-CFC
(mixed lineages: erythroid/granulocyte/macrophage/
megakaryocyte) or E
d/mac-CFC (data not shown). Therefore,
BP1 expression in the erythroid lineage targeted speciﬁcally
deﬁnitive erythroid progenitors.
In summary, our ﬁndings demonstrate that high expression
of BP1 leads to decreased adult b-globin gene expression and
inhibition of deﬁnitive erythroid differentiation. Together,
previous in vitro studies and the data presented here support
the concept that sustained BP1 expression, through repression
of the adult b-globin gene, may cause globin chain imbalance
resulting in thalassemia. Future studies should be directed to
determining the role of BP1 in human thalassemia.
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